Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Researchers look for measurable changes in a tumor before and after treatment: more immune cells reaching tumor tissue, stronger antigen-presentation and inflammatory signals, and changes in immune-suppressive features. They combine tissue and blood assays, pathology, gene-expression tests, and sometimes imaging. No single marker or universally accepted cutoff proves that a tumor has become “hot,” and an immune change is not the same as tumor shrinkage or longer survival.
What “cold” and “hot” mean in a tumor
“Cold” and “hot” are shorthand descriptions of a tumor’s immune environment, not standardized diagnostic categories with one agreed test. Researchers use the terms to summarize several features: whether T cells are present, where they are located, whether the tumor can display antigens for immune recognition, and whether inflammatory signals and the surrounding tissue support immune activity. A review published in 2026 discusses this complexity, but the sources available here do not identify a universal regulator- or standards-body definition or conversion threshold. Read the review on turning cold tumors hot.
A tumor can contain immune cells without those cells effectively attacking cancer. For example, T cells may accumulate around the tumor’s edge instead of entering tumor nests. Cells within the tissue may also be dysfunctional or constrained by regulatory T cells, suppressive myeloid cells, tumor biology, or limited vascular access. Consequently, a cell count by itself does not establish that a tumor is newly susceptible to immune attack. Spatial location and the balance of activating and suppressive signals matter too. A 2022 study of tumor immune and vascular phenotypes examines why static, single-site assessments can miss important context.
How the before-and-after comparison works
The central question is whether treatment changed the tumor’s measurable immune features. To answer it, investigators establish a pretreatment baseline and compare it with an assessment after therapy. A single post-treatment biopsy can describe what was present at that moment, but without a baseline it cannot show that treatment caused a change. Paired samples are more informative, although they still represent selected tissue from particular lesions and time points rather than a complete map of disease.
#1 Best Overall
- Characterize the baseline. Before treatment, collect tumor tissue and, depending on the study, blood or imaging data. Record which lesion and tissue compartment were sampled. A biopsy from one site cannot establish that every tumor lesion has the same immune environment.
- Choose a biologically relevant follow-up time. Repeat sampling after treatment at a point when the expected immune response could be detected. Timing affects whether a temporary change is captured. In one phase 0 interferon-gamma (IFNγ) study, biopsies were taken before treatment and 1–3 days after the final dose.
- Measure cells and their positions. Determine which immune populations are present, how abundant they are, and whether they are at the tumor margin or within tumor tissue.
- Assess recognition and inflammatory signals. Test whether tumor cells show changes in antigen-presentation machinery and whether inflammatory or immune-recruiting programs have shifted.
- Look for countervailing immune suppression. Measure inhibitory features alongside signs of activation; treatment can induce both.
- Compare biological findings with clinical outcomes. Report immune biomarkers separately from tumor response, survival, and toxicity. A biological shift alone does not establish that a therapy benefits patients.
Not every study can obtain repeat tumor samples, and sampling plans depend on the treatment, cancer, and practical feasibility. Investigators must interpret a paired result in light of the sampled lesion, tissue compartment, assay, and time point rather than treating it as a whole-body measurement.
What the main tests measure
Different methods answer different questions. Some quantify cell populations in tissue that has been dissociated; others preserve tissue architecture or measure molecular signals. No one test supplies all the information needed to characterize a tumor’s immune state.
| Approach | What it can show | What it cannot establish on its own |
|---|---|---|
| Flow cytometry on tumor tissue | Identifies and quantifies immune-cell populations in a tissue sample, including T-cell frequencies. | Because the tissue is dissociated, a cell frequency alone does not show where those cells were located in intact tissue or whether they were functioning effectively. |
| Immunohistochemistry or multiplex immunohistochemistry | Detects selected markers in tissue sections; multiplex approaches can assess more than one marker and help retain spatial context. | A section is a snapshot of the sampled tissue, not a complete view of all lesions or changes over time. |
| Multiplex immunofluorescence | Can examine multiple markers and cell relationships in intact tissue, including whether immune cells are near tumor cells. | It remains dependent on the sampled site, tissue, markers, and time point. |
| Gene-expression profiling | Assesses expression of genes involved in antigen processing and presentation, interferon response, inflammation, or immune recruitment. | A molecular signature indicates a measured state; by itself it does not prove effective tumor killing or clinical benefit. |
| Blood and serum cytokine assays | Measure circulating immune signals, such as serum cytokines, that can complement tissue observations. | A blood measurement does not specify what is happening inside a particular tumor lesion. |
| Reflectance confocal microscopy | In specific skin-cancer research settings, can examine inflammation, vessel features, and leukocyte trafficking in vivo and correlate observations with pathology and molecular data. | It is a study-specific complementary method, not a universal replacement for biopsy or an established routine standard across cancer types. |
In practice, a study may combine methods. Flow cytometry can quantify a cell population, while tissue imaging helps locate cells in relation to tumor structures. Gene-expression profiling can test for an inflammatory program, while blood assays add a systemic measurement. Agreement across complementary readouts can strengthen the description of immune remodeling, but it still does not turn a biomarker panel into a direct measure of patient benefit.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsRank #2
- Cancer Immunotherapy Principles and Practice
- ABIS BOOK
- Demos Medical Publishing
Which immune changes researchers look for
T-cell abundance and location
Researchers often assess CD3- or CD8-positive T cells and ask whether their frequency changes after treatment. They also need to consider where those cells sit: cells inside tumor nests suggest a different pattern from cells that remain at the edge. Other immune populations matter because an increase in one cell type may occur alongside populations that restrain immune activity.
Antigen presentation and tumor visibility
Major histocompatibility complex class I (MHC-I; called HLA in humans) displays peptide antigens on tumor-cell surfaces for immune recognition. Studies may measure surface MHC-I/HLA or expression of genes involved in antigen processing and presentation. An increase can support the idea that tumor cells have become more visible to immune cells, but it is evidence of a biological feature—not proof that immune cells recognized and eliminated the cancer.
Inflammatory and recruitment signals
Investigators may examine interferon-responsive gene expression, cytokines, and chemokines such as CXCL10. These measurements help characterize whether inflammatory or immune-cell recruitment programs changed. The interpretation depends on where a signal was measured, how it changed from baseline, and whether the study also found relevant immune cells in the tumor.
Immune brakes and suppressive context
Activation can trigger feedback inhibition. Programmed death-ligand 1 (PD-L1), for example, may rise on tumor cells or tumor-infiltrating myeloid cells. A report that only emphasizes increased T cells or inflammatory signals can therefore miss countervailing changes. A more useful account presents suppressive markers and cell populations alongside evidence of activation, rather than treating “hotter” as a one-directional scale.
Free tools Windows power users keep installed
One-click scans. No signup required.
What the phase 0 IFNγ study illustrates
A concrete example comes from a phase 0 clinical trial reported by Zhang and colleagues in 2019. The study enrolled 8 patients with synovial sarcoma or myxoid/round cell liposarcoma and administered weekly systemic IFNγ. Investigators obtained tumor biopsies before and after treatment and used flow cytometry, multiplex immunohistochemistry, gene-expression profiling, and serum cytokine assays. The trial report describes its methods and findings.
The investigators reported increased tumor-surface MHC-I and significant T-cell infiltration. In the analyzed samples, median tumor T-cell frequency was 0.14% before treatment and 0.82% after treatment; the paired comparison had p=0.03. They also observed increased PD-L1 on tumor-infiltrating myeloid cells (p=0.03). These findings illustrate why researchers measure both immune activation and feedback inhibition: the same intervention can shift more than one part of the tumor environment.
Rank #4
Three of the 7 evaluable patients had newly emergent antigen-specific humoral and/or T-cell responses. In two individual patients whose tumor-cell PD-L1 percentages had been below 5% before treatment, post-treatment percentages were 64% and 15%, respectively. Those two values describe individual observations, not cohort-wide response rates. The trial authors concluded that IFNγ changed the tumor microenvironment in the studied sarcomas, including MHC-I expression and T-cell infiltration. Because this was a small phase 0 study in specific cancers, its immune findings demonstrate the feasibility of measuring remodeling; they do not show that IFNγ improves outcomes or that the observations generalize to other tumors.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why imaging and tissue sampling are complementary
A biopsy preserves tissue for cellular and molecular assays, but it samples a limited location at a particular time. Tumors can vary between lesions and within a lesion, and a static sample may not capture movement or a transient immune change. These constraints make it risky to assign a single hot-or-cold label from one specimen or to assume that one biopsy predicts every tumor site.
In a 2022 study, researchers investigated in-vivo reflectance confocal microscopy in skin cancers to characterize inflammation, vascular features, and leukocyte trafficking, correlating those observations with pathology and molecular data. The study’s focus on dynamic vascular-inflammation phenotypes responds to limitations of static pathology-based phenotyping from single-time, single-site biopsies for predicting response. It does not establish confocal microscopy as a universal test: its role is complementary and specific to the setting studied. See the 2022 study.
Best Value
When choosing a measurement strategy, researchers weigh what feature they need to observe, whether tissue architecture must be preserved, whether dynamic behavior matters, and whether serial measurements are feasible. They also need to establish that the assay and interpretation fit the cancer type and treatment being studied.
How to interpret a reported “cold-to-hot” result
A careful report identifies the measured feature and compares it with baseline. “More T cells” is more precise than simply saying “the tumor became hot,” especially if the study does not establish cell location, function, or changes in other immune populations. A convincing account of remodeling may include several aligned measurements—such as increased infiltration, altered antigen-presentation signals, and inflammatory gene expression—while also noting suppressive changes.
- Biomarker change: a measured difference in a cell population, protein, cytokine, or gene-expression signal.
- Target engagement or immune remodeling: evidence that treatment affected a biological feature or the tumor’s immune environment.
- Tumor response: a clinical or pathological assessment of whether cancer burden or tumor tissue changed.
- Patient benefit: outcomes such as progression-free or overall survival, considered alongside harms such as toxicity.
These are related but distinct levels of evidence. A change in an immune marker may support a mechanism without demonstrating tumor control. Clinical response, survival, and toxicity should therefore be reported separately from biomarker findings. Results also need to be interpreted for the specific population, intervention, assay, and study design rather than generalized from an early-phase observation.
Why there is no single conversion cutoff
The “hot” and “cold” labels combine multiple biological dimensions, and the available sources do not establish a validated universal threshold for deciding that a tumor has converted. A threshold would also have to be meaningful for the relevant cancer type, treatment, assay platform, tissue site, and sampling schedule. Until such a standard is established for a particular context, readers should ask what the study actually measured and how the result relates to clinical outcomes instead of treating the label as a standalone diagnosis.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
